158 related articles for article (PubMed ID: 15266895)
1. Helicase primase: targeting the Achilles heel of herpes simplex viruses.
Kleymann G
Antivir Chem Chemother; 2004 May; 15(3):135-40. PubMed ID: 15266895
[TBL] [Abstract][Full Text] [Related]
2. Helicase-primase inhibitors for herpes simplex virus: looking to the future of non-nucleoside inhibitors for treating herpes virus infections.
Biswas S; Sukla S; Field HJ
Future Med Chem; 2014 Jan; 6(1):45-55. PubMed ID: 24358947
[TBL] [Abstract][Full Text] [Related]
3. Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease.
Crute JJ; Grygon CA; Hargrave KD; Simoneau B; Faucher AM; Bolger G; Kibler P; Liuzzi M; Cordingley MG
Nat Med; 2002 Apr; 8(4):386-91. PubMed ID: 11927945
[TBL] [Abstract][Full Text] [Related]
4. New antiviral drugs that target herpesvirus helicase primase enzymes.
Kleymann G
Herpes; 2003 Aug; 10(2):46-52. PubMed ID: 14577954
[TBL] [Abstract][Full Text] [Related]
5. ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2.
Chono K; Katsumata K; Kontani T; Kobayashi M; Sudo K; Yokota T; Konno K; Shimizu Y; Suzuki H
J Antimicrob Chemother; 2010 Aug; 65(8):1733-41. PubMed ID: 20534624
[TBL] [Abstract][Full Text] [Related]
6. Superior efficacy of helicase-primase inhibitor BAY 57-1293 for herpes infection and latency in the guinea pig model of human genital herpes disease.
Baumeister J; Fischer R; Eckenberg P; Henninger K; Ruebsamen-Waigmann H; Kleymann G
Antivir Chem Chemother; 2007; 18(1):35-48. PubMed ID: 17354650
[TBL] [Abstract][Full Text] [Related]
7. Helicase-primase as a target of new therapies for herpes simplex virus infections.
James SH; Larson KB; Acosta EP; Prichard MN
Clin Pharmacol Ther; 2015 Jan; 97(1):66-78. PubMed ID: 25670384
[TBL] [Abstract][Full Text] [Related]
8. High conservation of herpes simplex virus UL5/UL52 helicase-primase complex in the era of new antiviral therapies.
Collot M; Rouard C; Brunet C; Agut H; Boutolleau D; Burrel S
Antiviral Res; 2016 Apr; 128():1-6. PubMed ID: 26826441
[TBL] [Abstract][Full Text] [Related]
9. The helicase-primase inhibitor BAY 57-1293 reduces the Alzheimer's disease-related molecules induced by herpes simplex virus type 1.
Wozniak MA; Frost AL; Itzhaki RF
Antiviral Res; 2013 Sep; 99(3):401-4. PubMed ID: 23867133
[TBL] [Abstract][Full Text] [Related]
10. Antiviral drug resistance and helicase-primase inhibitors of herpes simplex virus.
Field HJ; Biswas S
Drug Resist Updat; 2011 Feb; 14(1):45-51. PubMed ID: 21183396
[TBL] [Abstract][Full Text] [Related]
11. Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293.
Betz UA; Fischer R; Kleymann G; Hendrix M; Rübsamen-Waigmann H
Antimicrob Agents Chemother; 2002 Jun; 46(6):1766-72. PubMed ID: 12019088
[TBL] [Abstract][Full Text] [Related]
12. Mutations close to functional motif IV in HSV-1 UL5 helicase that confer resistance to HSV helicase-primase inhibitors, variously affect virus growth rate and pathogenicity.
Biswas S; Tiley LS; Zimmermann H; Birkmann A; Field HJ
Antiviral Res; 2008 Oct; 80(1):81-5. PubMed ID: 18539344
[TBL] [Abstract][Full Text] [Related]
13. New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease.
Kleymann G; Fischer R; Betz UA; Hendrix M; Bender W; Schneider U; Handke G; Eckenberg P; Hewlett G; Pevzner V; Baumeister J; Weber O; Henninger K; Keldenich J; Jensen A; Kolb J; Bach U; Popp A; Mäben J; Frappa I; Haebich D; Lockhoff O; Rübsamen-Waigmann H
Nat Med; 2002 Apr; 8(4):392-8. PubMed ID: 11927946
[TBL] [Abstract][Full Text] [Related]
14. Helicase-primase inhibitor amenamevir for herpesvirus infection: Towards practical application for treating herpes zoster.
Shiraki K
Drugs Today (Barc); 2017 Nov; 53(11):573-584. PubMed ID: 29451274
[TBL] [Abstract][Full Text] [Related]
15. Drugs in development for herpes simplex and varicella zoster virus.
Birkmann A; Zimmermann H
Clin Pharmacol Ther; 2017 Jul; 102(1):30-32. PubMed ID: 28160282
[TBL] [Abstract][Full Text] [Related]
16. High frequency of spontaneous helicase-primase inhibitor (BAY 57-1293) drug-resistant variants in certain laboratory isolates of HSV-1.
Biswas S; Swift M; Field HJ
Antivir Chem Chemother; 2007; 18(1):13-23. PubMed ID: 17354648
[TBL] [Abstract][Full Text] [Related]
17. A single drug-resistance mutation in HSV-1 UL52 primase points to a difference between two helicase-primase inhibitors in their mode of interaction with the antiviral target.
Biswas S; Kleymann G; Swift M; Tiley LS; Lyall J; Aguirre-Hernández J; Field HJ
J Antimicrob Chemother; 2008 May; 61(5):1044-7. PubMed ID: 18299638
[TBL] [Abstract][Full Text] [Related]
18. Herpes simplex virus helicase-primase inhibitors: recent findings from the study of drug resistance mutations.
Biswas S; Field HJ
Antivir Chem Chemother; 2008; 19(1):1-6. PubMed ID: 18610552
[TBL] [Abstract][Full Text] [Related]
19. Oral bioavailability and in vivo efficacy of the helicase-primase inhibitor BILS 45 BS against acyclovir-resistant herpes simplex virus type 1.
Duan J; Liuzzi M; Paris W; Liard F; Browne A; Dansereau N; Simoneau B; Faucher AM; Cordingley MG
Antimicrob Agents Chemother; 2003 Jun; 47(6):1798-804. PubMed ID: 12760851
[TBL] [Abstract][Full Text] [Related]
20. HSV antivirals - current and future treatment options.
Birkmann A; Zimmermann H
Curr Opin Virol; 2016 Jun; 18():9-13. PubMed ID: 26897058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
